Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine [0.03%]
克服癌症治疗多重耐药性的高级策略：P-糖蛋白抑制剂、药物递送和个性化医疗方面的进展
Ankitha Harish,N Deepika,Vedamurthy Joshi et al.
Ankitha Harish et al.
Multidrug resistance (MDR) appears to be a major challenge in cancer treatment, frequently leading to suboptimal clinical results and treatment failure. A transmembrane efflux pump called P-glycoprotein (P-gp) is essential to multidrug resi...
Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study [0.03%]
低剂量venetoclax联合地西他滨治疗中国老年急性髓系白血病患者的安全性和有效性：一项单中心真实世界研究
Xian Li,Xin-Yi Zhu,Xi-Bin Xiao et al.
Xian Li et al.
Acute myeloid leukemia (AML) carries a poor prognosis in elderly or medically unfit patients, with median overall survival (OS) of only 7-8 months for those ineligible for intensive chemotherapy. While venetoclax (VEN) combined with azaciti...
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy [0.03%]
超越表面：癌症治疗中针对SLC转运蛋白组和非经典药物转运机制
Srikruthi Kunigal Sridhar,Kasim Sakran Abass,Buduru Gowthami et al.
Srikruthi Kunigal Sridhar et al.
The solute carrier (SLC) superfamily comprises a broad array of membrane-bound transport proteins that are integral to the intracellular uptake of various substrates, including nutrients, endogenous metabolites, and an expanding repertoire ...
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021 [0.03%]
2013年至2021年我国成人I期肿瘤临床试验中研究药物的风险和获益评估情况分析
Zhizhou Liang,Yu Yang,Yichen Zhang et al.
Zhizhou Liang et al.
Previous research shows that the benefits of phase-I oncology trials increased from 5 to 18% between 2000 and 2019 globally. However, the risk-benefit profile of phase-I trials in China is unclear. This study aims to analyze the risk-benefi...
Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors [0.03%]
抗体偶联药物在晚期实体瘤末线治疗早期临床试验中的潜在价值
Ippei Miyamoto,Takahiro Kogawa,Kana Kurokawa et al.
Ippei Miyamoto et al.
Recently, comprehensive genomic profiling (CGP)-matched therapy and antibody-drug conjugates (ADCs) have garnered increased attention. However, their response rates and prognoses in early-phase clinical trials are not yet widely appreciated...
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α-p300/CBP alliance [0.03%]
攻克肿瘤低氧微环境：抑制HIF-1α-p300/CBP致癌联盟的研究进展
Emadeldin M Kamel,Sally Mostafa Khadrawy,Ahmed A Allam et al.
Emadeldin M Kamel et al.
The ability of tumor cells to survive under low-oxygen conditions is largely attributed to the hypoxia-inducible factor-1 (HIF-1) pathway, in which HIF-1α forms a functional complex with the transcriptional co-activators p300/CBP. This int...
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors [0.03%]
口服细菌补充剂（EDP1503）联合派姆单抗Ⅰ/Ⅱ期、开放标签研究，用于治疗晚期或转移性微卫星稳定型结直肠癌、三阴性乳腺癌和免疫检查点抑制剂复发肿瘤的受试者
Judy S Wang,Edward R Arrowsmith,J Thaddeus Beck et al.
Judy S Wang et al.
We report a phase 1/2 study evaluating EDP1503 (capsule containing Bifidobacterium animalis lactis) ± pembrolizumab in participants with microsatellite-stable colorectal cancer (MSS CRC), triple-negative breast cancer (TNBC), or other tumo...
Sarah Qutayba Badraldin,Karar H Alfarttoosi,Hayder Naji Sameer et al.
Sarah Qutayba Badraldin et al.
Kinesin family member 15 (KIF15), a kinesin superfamily motor protein, is known to be involved in mitotic spindle formation and chromosome movement during cell division. Recent research has determined KIF15 to be a crucial regulator in seve...
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis [0.03%]
派姆单抗致心肌炎的临床特征、治疗及预后
Zhaoquan Wu,Wei Sun,Chunjiang Wang
Zhaoquan Wu
To explore the regularity and clinical characteristics of pembrolizumab induced myocarditis, and to provide a reference for the diagnosis and treatment of myocarditis. Clinical reports of pembrolizumab induced myocarditis were collected by ...
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer [0.03%]
抗CD47三特异性杀伤衔接器可增强NK细胞对肺癌的细胞毒性作用
Chutipa Chiawpanit,Yupanun Wutti-In,Somsakul Pop Wongpalee et al.
Chutipa Chiawpanit et al.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with immune evasion posing a major therapeutic challenge. One key mechanism involves the 'don't eat me' signal mediated by the interaction between CD47 and signal reg...